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ABSTRACT
Aim Acute bronchiolitis is the commonest cause for
hospitalisation in infancy. Supportive care remains the
cornerstone of current management and no other
therapy has been shown to inﬂuence the course of the
disease. It has been suggested that adding nebulised
hypertonic saline to usual care may shorten the duration
of hospitalisation. To determine whether hypertonic
saline does have beneﬁcial effects we undertook an
open, multi-centre parallel-group, pragmatic RCT in ten
UK hospitals.
Methods Infants admitted to hospital with a clinical
diagnosis of acute bronchiolitis and requiring oxygen
therapy were randomised to receive usual care alone or
nebulised 3% hypertonic saline (HS) administered
6-hourly. Randomisation was within 4 h of admission.
The primary outcome was time to being assessed as
‘ﬁt’ for discharge with secondary outcomes including
time to discharge, incidence of adverse events together
with follow up to 28 days assessing patient centred
health related outcomes.
Results A total of 317 infants were recruited to the
study. 158 infants were randomised to HS (141
analysed) and 159 to standard care (149 analysed).
There was no difference between the two arms in time
to being declared ﬁt for discharge (hazard ratio: 0−95,
95% CI: 0.75−1.20) nor to actual discharge (hazard
ratio: 0.97, 95% CI: 0.76−1.23). There was no
difference in adverse events. One infant in the HS group
developed bradycardia with desaturation.
Conclusion This study does not support the use of
nebulised HS in the treatment of acute bronchiolitis over
usual care with minimal handlings.
ClinicalTrials.gov registration number
NCT01469845.
INTRODUCTION
Acute bronchiolitis is the most common cause for
hospitalisation in infancy with 1%–3% of all
infants being admitted during their ﬁrst winter.1–4
The disease is caused by a number of common
respiratory viruses, with respiratory syncytial virus
(RSV) the most commonly identiﬁed, and is asso-
ciated with the characteristic winter peaks in admis-
sions.1–7 Infants typically develop signs of an upper
respiratory tract infection with rhinitis followed by
signs of lower respiratory tract involvement due to
lower airway obstruction. This is manifest by
increased work of breathing, hyperinﬂation, cough
and widespread crackles on auscultation which may
or may not be accompanied by wheeze.1–5 The
peak age incidence of babies admitted to hospital
with this condition is between 1 and 6 months.1–9
Supportive care, with supplemental oxygen to
correct hypoxia, minimal handling to minimise the
risk of exhaustion and the provision of ﬂuids,
remains the cornerstone of management.1–5 7–11
The introduction of oxygen therapy, over 60 years
ago, reduced mortality rates from as high as 20%
in the 1940s11 to substantially <1%,12 13 though
worldwide it remains a major cause for infant
death.14 In the UK, admissions for acute bronchio-
litis increased from 21 330 in 2004/2005 to 33 472
in 2010/2011,15 placing enormous strains on paedi-
atric in-patient services and paediatric intensive
care units16 which sometimes have to close due to
the numbers of infants with acute bronchiolitis.
The mean duration for admission in the UK is
around 3.3 days,17 compared with a median of
1.5 days for all acute paediatric admissions.18 Since
the introduction of oxygen therapy, antiviral
agents, oral and inhaled steroids and a variety of
bronchodilators have neither decreased lengths of
inpatient stay nor impacted on the course of the
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What is the key question?
▸ Does nebulised hypertonic saline inﬂuence the
duration of hospitalisation when used to treat
infants with acute bronchiolitis?
What is the bottom line?
▸ Nebulised hypertonic saline does not reduce
the length of stay in infants hospitalised with
acute bronchiolitis.
Why read on?
▸ This deﬁnitive multicentre study will directly
inﬂuence clinical care to prevent the adoption
of an ineffective treatment and provide a model
for the conduct of future studies involving
inhaled therapy in this condition.
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acute illness,1–4 7–10 while an effective vaccine still appears
someway off.19
Some studies published over the past 8 years have suggested
that nebulised hypertonic saline (HS) may inﬂuence the course
of the illness and reduce the duration of hospitalisation. A
Cochrane review concluded that, ‘nebulized 3% saline may sig-
niﬁcantly reduce the length of hospital stay and improve the
clinical severity score in infants with acute viral bronchiolitis’.20
The studies included in the review were undertaken in a diverse
range of healthcare settings with a range of therapies and com-
parators. HS was used at 3% and 6%, with and without a bron-
chodilator and compared, in most studies, with nebulised
normal saline with and without other agents. Some authors
have suggested that normal saline can impact favourably on the
clinical outcomes and, as such, is an active comparator,21 while
older studies using distilled water as the ‘control’ agent were cri-
ticised on the basis that the hypo-osmolar water could induce
bronchospasm. A further challenge in interpreting these studies
is that the term ‘acute bronchiolitis’ is used to describe pheno-
typically different patients in different parts of the world. The
above deﬁnition in which widespread crackles are a characteris-
tic ﬁnding is used in the UK, Australia and a number of other
countries, while in the USA and other countries it is used to
describe the ﬁrst episode of wheezing with an apparent viral
infection.1–4 7 While the underlying pathology, dominated by
neutrophil inﬂux into the airway,22 may be very similar in most
of these patients, the latter deﬁnition would include a signiﬁcant
proportion of infants experiencing a ﬁrst viral exacerbation of
asthma.
In light of these challenges, a multicentre, randomised, open,
pragmatic study was undertaken in which infants requiring
oxygen therapy for acute bronchiolitis were randomised to
receive usual care or usual care with 4 mL nebulised 3% HS
6-hourly until they were ﬁt for discharge.
METHODS
The carers of all randomised participants provided written
informed consent. The study was approved by the South
Yorkshire Research Ethics Committee and registered with
ClinicalTrials.gov, number NCT01469845.
Study design and participants
Hypertonic Saline in Acute Bronchiolitis Rct and Economic
evaluation (SABRE) was a multicentre, parallel-group, open,
randomised controlled trial with a 1:1 allocation ratio. An eco-
nomic evaluation alongside the trial will be reported separately.
This report is compliant with CONsolidated Standards of
Reporting Trials (CONSORT) 2010.23 Participants were
recruited from the assessment units and paediatric wards of 10
participating centres in England and Wales between October
2011 and December 2013.
Eligible participants were healthy infants under 1 year of age
needing supplementary oxygen for oxygen saturations of <92%
in air when admitted to hospital with a clinical diagnosis of
acute bronchiolitis. This was deﬁned as an apparent viral
respiratory tract infection associated with airways obstruction
manifest by hyperinﬂation, tachypnoea and subcostal recession
with widespread crepitations on auscultation.8 The time of
admission was deﬁned as when the paediatrician, or paediatric
Advanced Nursing Practitioner, made the decision to admit.
Eligible participants required supplemental oxygen therapy on
admission and were consented and randomised within 4 h of
admission. The following were exclusion criteria: a history of
wheezy bronchitis or asthma; gastro-oesophageal reﬂux;
previous lower respiratory tract infections; risk factors for
severe disease; carers lacking ﬂuent English in the absence of
translational services and patients requiring admission to high
dependency or intensive care units (HDU/ICU) at presentation.
Allocation was either to standard supportive care (control) or
oxygen as required, and ﬂuid administration plus 4 mL nebu-
lised 3% HS solution (PARI MucoClear) every 6 h, administered
by a nurse via the PARI Sprint nebuliser with appropriate face
mask (intervention). The nebuliser and face mask were pur-
chased from (PARI Medical, UK). The saline treatment was dis-
continued once the primary outcome had been achieved. All
concomitant medications were recorded. Centres were encour-
aged to discontinue antibiotics at admission if previously pre-
scribed, but antibiotics were permissible for suspected secondary
bacterial infection in line with UK guidance.8 Standard support-
ive care involved oxygen as required, minimal handling and
ﬂuid administration as appropriate to the severity of the disease.
The ﬁnal protocol with details of amendments are documen-
ted elsewhere.24 Initially, patients were to be randomised within
90 min of a decision to admit, but an amendment permitted
this to be extended to 240 min given the practical difﬁculties of
meeting the 90 min deadline.
Randomisation and masking
After parental informed consent was obtained, infants were ran-
domised using a centralised web-based randomisation system
with a computer generated algorithm generated by Shefﬁeld
Clinical Trials Research Unit. Randomisation was conducted in
randomly ordered blocks of size two, four and six stratiﬁed by
hospital. This was an open study when blinding was not
possible.
Outcomes
The primary outcome was the time until the infant was assessed
as being ‘ﬁt for discharge’, which was deﬁned as the point at
which the infant was feeding adequately (taking >75% of their
usual intake) and had been in air with a saturation of at least
92% for 6 h. Data was collected on a daily basis from the rou-
tinely recorded clinical observations from which the two key
outcomes, time ﬁt for discharge and time to actual discharge
were calculated. Secondary outcomes included actual time to
discharge; readmission within 28 days from randomisation;
adverse events; healthcare usage and duration of respiratory
symptoms postdischarge. Parents were also asked to complete a
validated infant and parental quality of life using the Infant
Toddler Quality of Life (ITQoL) questionnaire 28 days after ran-
domisation.25 Data was collected on the ward in a case report
form and, after discharge, in a symptom and health service
usage diary.
Statistical analysis
Based on data taken from UK hospital episode statistics, we
expected an average time to discharge of around 3 days with an
SD of 32 h. Assuming a conservative SD of 46 h, in order to
have 90% power to detect a 25% difference in time to meeting
discharge criteria, the study needed 139 patients per group at a
two-sided α level of 5%; this corresponds to an HR of approxi-
mately 0.7 on a log-rank test.
The recruitment period was extended to overcome slow
recruitment. At the request of the data monitoring committee,
we undertook one unplanned interim analysis for efﬁcacy using
a 1% signiﬁcance level after 152 patients were recruited, with
the ﬁnal signiﬁcance level adjusted downwards to 4.5%.26 The
interim analysis report was restricted to the data monitoring
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committee. All other facets of the analysis remained unchanged
from the prespeciﬁed analysis plan, which was written prior to
data, being available to the statisticians.
The primary outcome was analysed by a Cox proportional
hazards regression model in which the centre was ﬁtted as a
ﬁxed effect. Proportional hazards was assessed by plotting
scaled Schoenfeld residuals against time.27 We also assessed
whether HS worked similarly in RSV+ and RSV− patients by
including RSV status and its interaction with treatment group.
The proportion of patients admitted to HDU/ICU and the
proportion readmitted to hospital were compared between treat-
ment groups by logistic regression, again with centre as a covari-
ate. Each of the nine dimensions of the ITQoL study was
analysed by a Mann–Whitney U test. All analyses presented are
by intention to treat unless otherwise stated. Analyses were con-
ducted using SPSS V. 20 or SAS V. 9.3.
Role of the funding source
The funder was not involved in the trial design, patient recruit-
ment; data collection, analysis, interpretation, or presentation;
writing or editing of the report; or the decision to submit for
publication. The corresponding author had full access to all the
data in the study and had ﬁnal responsibility for the decision to
submit for publication.
RESULTS
The trial randomised 317 infants between 26 October 2011 and
23 December 2013, when it closed having reached full accrual,
with 158 patients allocated to the nebulised 3% HS group and
159 allocated to usual care (ﬁgure 1). Twenty-six out of 317
participants were excluded as being ineligible when randomised,
and medical notes were incomplete for one eligible participant,
leaving 290 participants included in the primary analysis.
Baseline demographics are displayed in table 1. In the
intention-to-treat (ITT) population, in which patients were ana-
lysed by their original assigned groups, there were 142 partici-
pants in the HS arm and 149 in the control arm. One
intervention group patient did not have any date and time of ﬁt
for discharge recorded and are not included in any of these ana-
lyses, but were known to be discharged on day 6 (i.e. between
120 h and 144 h); this length of stay (LoS) is similar enough to
the remainder for their missing data to have no material impact.
Five participants did not receive treatment as scheduled; a sensi-
tivity (per protocol) analysis, in which these ﬁve participants
were excluded, gave almost identical results as ITT analyses
(data not shown).
In intent-to-treat analyses (HS n=141; control 149, except
where stated), there was no observed difference between the two
treatment arms, either in the time to being declared ﬁt for dis-
charge (HR=0.95, 95% CI 0.75% to 1.20%; p=0.66; ﬁgure 2)
or in the time to actual discharge (HR=0.97, 95% CI 0.76 to
1.23; ﬁgure 3 and table 2). The median time to being declared ﬁt
for discharge was 76 h from admission in each group, and the
time to actual discharge was 89 h in each group. RSV+ status
(n=179, median 80.6 h) was associated with a longer time until
ﬁtness for discharge than observed in RSV− patients (n=27,
median 50.8 h) (HR=1.94, 95% CI 1.24% to 3.02%; p=0.004)
and a longer time to actual discharge (medians 91.1 h versus
72.2 h, HR=1.47, 95% CI 0.95% to 2.28%; p=0.09), but there
was no evidence of any interaction between treatment effect and
viral status (p=0.59 for time to ﬁt for discharge and p=0.41 for
time to actual discharge). Viral testing was not undertaken in 79
patients in line with routine practice in some centres.
There was no evidence to suggest a difference between treat-
ment groups in terms of the numbers admitted to HDU/ICU or
readmitted within 28 days of randomisation (table 3). No
important differences were observed on any of the ITQoL
dimensions (ﬁgure 4: HS n=54; control 49) and there was no
evidence that outcomes differed between groups according to
RSV status.
Six adverse events were possibly related to saline treatment,
including one serious adverse event (SAE), bradycardia and
desaturation during administration of the nebuliser, which
resolved the following day. The remaining ﬁve non-SAEs were:
bradycardia (self-correcting), desaturation, coughing ﬁt and
increased respiratory rate (all of which were resolved within
1 day); and a chest infection which resolved after 6 days.
DISCUSSION
The data generated in this randomised study indicate that adding
6-hourly nebulised 3% HS to usual care when treating infants
admitted to hospital with acute bronchiolitis has no discernible
beneﬁcial or harmful consequences when compared with usual
care alone. In particular, there was no change in either the time
taken for infants to be assessed as being ﬁt for discharge or in the
actual time to discharge. Furthermore, the intervention had no
impact on admissions to HDU/ICU, readmission rates, or reported
morbidity in the month following the acute illness. Moreover, the
conclusion is unaffected by whether the acute illness was caused
by the RSV or one of the many other respiratory viruses that can
cause the same clinical illness. Consistent with previous studies,
85% of tested infants were positive for RSV.
This is the largest study undertaken to investigate the poten-
tial for HS to inﬂuence the duration of admission among infants
hospitalised with acute bronchiolitis and its results highlight the
need for funding large well-designed, randomised, clinical trials
in paediatrics. The results are likely to contribute signiﬁcantly to
individual patient care and to resource usage in the healthcare
system by preventing the widespread introduction of an ineffect-
ive and time-consuming therapy.
Among the strengths of this study was the multicentre design
using both teaching hospitals and district general hospitals
which ensures that the results are generalisable to all paediatric
secondary care units admitting such infants. Moreover, the
study was designed to assess the potential role of this interven-
tion in the most severely affected infants, namely infants admit-
ted to hospital requiring supplemental oxygen therapy. Such
patients place a signiﬁcant burden on healthcare systems glo-
bally. Nebulised 3% HS was used because this was the concen-
tration used in the majority of previous studies, and because
there is a commercial product marketed for this indication. For
comparison, the concentration of salt in blood is 0.9% and that
in sea water 3.4% (3.2% to 3.8%). There is no indication from
the literature that other concentrations of HS would be more
effective than 3% saline.
A potential limitation of the study is the absence of blinding.
However, we believe that the use of an open pragmatic study
design is one of the strengths of the study. This approach was
chosen in order to avoid potential confounders and to deter-
mine whether the use of nebulised HS might have a place in
routine clinical practice. A number of previous studies involving
HS and other nebulised interventions, such as the antiviral
agent ribavirin, have used a randomised blinded approach using
either distilled water or normal saline as the nebulised placebo
agent. Both approaches have been criticised in that it is argued
that the hypo-osmolar distilled water can induce bronchocon-
striction, thus hindering the infant’s recovery, while some
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proponents of hypertonic therapy have argued that failure to
show a difference when compared with nebulised normal saline
is due to the beneﬁcial effects of the depositing normal saline in
the lower airways.21 The remarkable congruity in the outcomes
for both arms of the trial, as shown in ﬁgures 2 and 3, argue
against the inﬂuence of any bias resulting from this being a prag-
matic study, since any putative therapeutic or adverse effect
would have to be exactly matched by the effect of any systematic
bias. Moreover, the study was conducted in 10 centres with the
key outcomes being obtained by nurses using routinely recorded
clinical data. It is extremely unlikely that any systematic view of
the potential beneﬁts or harm would inﬂuence the many dozens
of medical staff involved in the care of these infants.
The study protocol imposed a restrictive time window within
which it was permissible to randomise. As a result, we excluded
from the study a number of otherwise eligible infants, whom
clinicians might consider appropriate candidates for treatment.
We have no reason to suppose that infants who entered the trial
were substantially different from those who did not, thus
biasing the results, but did not collect data on infants without
parental consent. The relatively limited data regarding effects of
quality of life and other outcomes during the ﬁrst month after
discharge was disappointing, but does not impact on the
primary outcome and major secondary outcomes.
There is good evidence that bronchoconstriction does not
contribute signiﬁcantly to the airways obstruction in infants
Figure 1 CONSORT diagram. ITQoL, Infant Toddler Quality of Life; ITT, intention-to-treat.
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with acute bronchiolitis which explains why bronchodilators do
not provide any beneﬁt.1–4 7–9 Instead, the obstruction appears
to be, in part, due to oedema within the airway wall and, prob-
ably more importantly, accumulation of inﬂammatory exudates
in the airways driven by the intense neutrophilia within the
lumen of the airways of affected infants.22 Signiﬁcant impair-
ment of mucocillary clearance due to shedding of ciliated cells,
probably, also contributes to accumulation of secretions in the
small airways. The suggested mode of action of HS is through
an alteration in mucus rheology as a result of improved hydra-
tion and the breaking of ionic bonds within the mucus leading
to improvements in mucocillary clearance of secretions.21 28
The observation that HS can increase ciliary beat frequency may
further enhance clearance. It is also suggested that this interven-
tion reduces mucosal wall oedema through osmotic effects.21 28
At present, there is no direct in vivo data to support the sugges-
tion that the luminal surface of the infected airways is effectively
Table 1 Demographics
Standard care plus
(intervention) (n=142)
Standard care
(control)
(n=149)
Age (months)
Mean (SD) 3.3 (2.6) 3.4 (2.8)
Median (range) 2.3 (0.3 to 11.5) 2.5 (0.3 to 11.5)
Birthweight (kg)
Median (range) 3.25 (1.87 to 9.4) 3.37 (1.81 to
8.2)
Gestation (weeks)
Mean (SD) 39.3 (1.7) 39.2 (1.8)
Weight at presentation (kg)
median (range)
5.10 (2.2 to 11.2) 5.70 (2.60 to
11.9)
Gender (%)
Male 73 (51.4) 85 (57.0)
Female 69 (48.6) 64 (43.0)
Smoker in household (%) 58 (41.7) 63 (42.3)
Infant in childcare (%) 8 (5.7) 10 (7.0)
Feeding on admission (%)
Breast 27 (19.0) 24 (16.2)
Bottle 103 (72.5) 120 (81.1)
Breast and bottle 12 (8.5) 4 (2.7)
Number of siblings (%)
0 33 (23.2) 27 (18.1)
1 52 (36.6) 62 (36.6)
2 or more 57 (40.2) 60 (45.3)
First-degree relative with
asthma (%)
58 (42.3) 64 (45.4)
Previous respiratory problems (%) 2 (1.4) 3 (2.0)
Used antibiotics in hospital (%) 29 (20.4) 24 (16.1)
Used oral steroids prior to
admission (%)
2 (1.4) – (–)
Used oral steroids in hospital (%) 3 (2.1) 1 (0.7)
Used β-2 agonist in hospital (%) 10 (7.0) 4 (2.7)
Used ipratropium hospital (%) 6 (4.2) 3 (2.0)
Used intravenous fluids in
hospital (%)
9 (6.3) 7 (4.7)
RSV status (%)
Positive 83 (58.5) 96 (64.4)
Negative 15 (10.6) 12 (8.1)
No virus identified 4 (2.8) 2 (1.3)
Not tested 40 (28.2) 39 (26.2)
RSV, respiratory syncytial virus.
Figure 2 Cumulative survival plot for time to being declared ﬁt for
discharge.
Figure 3 Cumulative survival plot for actual time to discharge.
Table 2 Time to being declared fit for discharge and time to
discharge (hours)
Intervention (n=142) Control (n=149)
Time to fit for discharge
Mean (SD) 90.4 (73.2) 88.9 (67.9)
Median (IQR) 75.6 (46.1 to 113.3) 75.9 (45.5 to 121.0)
(Range) (7.1 to 576.1) (6.8 to 565.9)
Missing 1 0
Time to discharge
Mean (SD) 100.6 (76.9) 101.3 (84.4)
Median (IQR) 88.5 (51.6 to 120.9) 88.7 (50.9 to 123.6)
(Range) (16.6 to 595.4) (4.2 to 857.4)
Missing 1 0
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in a dehydrated state in vivo, speciﬁcally in RVS bronchiolitis
and, hence, the failure of this therapy to impact on the clinical
outcomes may be attributed to the lack of impact on the under-
lying process. Alternatively, it is possible that insufﬁcient saline
is delivered to the distal conducting airways due to airﬂow
obstruction resulting from luminal secretions and mucosal
oedema. This seems unlikely, as we used a modern nebuliser
speciﬁcally designed for use in this age group which was well
tolerated, and the frequency of therapy was greater than that
used in some previous studies. While crying or distress may
adversely affect drug delivery,29 it was reported that infants tol-
erated the treatment extremely well. This was probably related
to their age, distress being more common in older infants and
toddlers.
The results of this trial conﬂict with the conclusions of a
Cochrane review, for which searches were last updated in April
2013–May 2013.20 The Cochrane team’s meta-analysis of ﬁve
trials (n=500) suggested HS-reduced LoS by more than 1 day
(mean difference −1.15, 95% CI −1.49 to 0.82 days) with mod-
erate levels of heterogeneity (I2=30). The summary effect size
and associated heterogeneity were both driven by two studies,
whose effect sizes made them outliers, each of which demon-
strated CIs two-thirds the size of SABRE’s from sample sizes of
93 and 112. Our own systematic review (PROSPERO
CRD42014007569), which has different inclusion criteria,
reckon there to be six eligible studies published since the
Cochrane group updated their searches and a further three not
found by the Cochrane review. Their synthesis will allow for a
more reliable estimate of summary effect and heterogeneity as
well as for a proper investigation of publication bias. None of
these studies reported a reduction in the LoS. This includes the
biggest study to date apart from SABRE,30 which also reported
a null result (−0.02, 95% CI −0.25 to 0.21 days). A further
study involving 160 hospitalised infants from Holland also
reported no difference in duration of hospitalisation when com-
paring 6% HS, 3% HS and normal saline.31
One issue that may have contributed to the differences
reported in the outcomes between this study and the Cochrane
review might be the use of the term ‘acute bronchiolitis’ which
can vary between countries, as noted in the introduction. The
patients recruited to this study met the standard British deﬁn-
ition with evidence of viral infection, airways obstruction and
widespread crackles in the chest with or without wheeze.
Studies included in the Cochrane review specify that they
included infants with a viral infection and wheeze. Hence, it is
possible that they may have included patients with similar but
different underlying pathologies. However, studies have demon-
strated the lack of precision in the use of the term ‘wheeze’,32 33
and in itself is unlikely to be a major issue particularly as the
inﬂammation observed in those with acute bronchiolitis and
‘wheezy bronchitis’ is likely to be very similar. Of those studies
included in the Cochrane review addressing the impact on LoS,
three studies included subjects with a median age of 4.3 months
or less suggesting that they were a very similar population to
those included in this study. Two Chinese studies included
patients with a median age of 5.8 months and in a Canadian
study this was 8.9 months. The inclusion of subjects older than
a year of age in these studies may have resulted in the inclusion
of a minority of asthmatic subjects though the impact of this on
the results is unclear. The patients in our study were well charac-
terised, and the results can be conﬁdently applied to the UK
healthcare system.
In summary, this large, multicentre, open, randomised trial
failed to demonstrate any impact on any of the clinically rele-
vant outcomes when nebulised 3% HS administered 6-hourly
was compared with good supportive care with minimal hand-
lings in acute severe bronchiolitis. It did not appear to be
responsible for a signiﬁcant number of adverse events.
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Intervention Control
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FAS, full analysis set.
Figure 4 ITQoL dimensions by study group, full analysis set (FAS).
ITQoL, Infant Toddler Quality of Life.
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